Sub-lobar resections for peripheral non-small cell lung cancer measuring ≤2 cm: Insights from recent clinical trials
The findings of two well conducted trials that randomised 1803 patients with a peripheral non-small cell lung cancer measuring ≤2 cm to a lobar to sub-lobar resection have established the latter as a new standard of care. It is important for non-surgical oncologists to appreciate the details of study design and outcomes of both studies, given the possible impact they have for considerations of stereotactic ablative radiot herapy (SABR) for operable patients with early-stage NSCLC. Differences in overall survival between the study populations highlight the impact of confounding factors like smoking history and comorbiditi...
Source: Radiotherapy and Oncology - January 13, 2024 Category: Radiology Authors: Suresh Senan, Famke L. Schneiders, Drew Moghanaki Tags: Commentary Source Type: research
Response to Evaluation of post-lung SABR imaging: a proposed pathway
We would like to thank De Bruycker et al. for their recent letter [1]. Their algorithm is well-outlined and provides a practical approach to assessing treatment response to help clinicians following patients after lung SABR. The focus on specific radiographic features suggestive of local recurrence should help improve the specificity of identifying recurrence. The specific features that they include are: sequential enlarging opacity, bulging margin, craniocaudal growth, loss of linear margin, and loss of air bronchogram [1]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - January 12, 2024 Category: Radiology Authors: Stephanie Gulstene, David A. Palma Tags: Letter to the Editor Source Type: research
The impact of transportation mode, socioeconomic deprivation and rurality on travel times to radiotherapy and surgical services for patients with prostate cancer: a national population-based evaluation
The centralisation of cancer services to high-volume centres across Europe and internationally has been undertaken for several cancer-specific surgical procedures based on evidence that centres performing higher volumes deliver better patient outcomes. [1] Whilst the rationale for centralisation of many types of cancer surgery has been established, there is also increasing evidence of a volume-outcome relationship to support centralisation of radiotherapy services, particularly for complex tumour types, such as head and neck cancer. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - January 12, 2024 Category: Radiology Authors: Lu Han, Richard Sullivan, Alison Tree, Daniel Lewis, Pat Price, Vijay Sangar, Jan van der Meulen, Ajay Aggarwal Tags: Original Article Source Type: research
Evaluation of post-lung SABR imaging: a proposed pathway
To the Editor, (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - January 10, 2024 Category: Radiology Authors: De Bruycker Aur élie, Schneiders Famke, Senan Suresh Tags: Letter to the Editor Source Type: research
Non-invasive decision support for clinical treatment of non-small cell lung cancer using a multiscale radiomics approach
Immunotherapy and targeted therapies have significantly transformed the treatment of various cancers. Immune checkpoint blockade with immunotherapeutic agents has shown promising results in the clinical management of lung cancer by preventing tumor cells from evading immune system surveillance [1,2]. Programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are the most extensively studied therapeutic targets. Accumulating studies have shown that the response to PD-1/PD-L1 immunotherapy is associated with tumor-infiltrating immune cells, to which immunoinflammatory tumors tend to respond [3,4]. (Sou...
Source: Radiotherapy and Oncology - January 7, 2024 Category: Radiology Authors: Xingping Zhang, Guijuan Zhang, Xingting Qiu, Jiao Yin, Wenjun Tan, Xiaoxia Yin, Hong Yang, Hua Wang, Yanchun Zhang Source Type: research
Worsening of 2-year patient-reported intestinal functionality after radiotherapy for prostate cancer including pelvic node irradiation
Intestinal toxicity (IT) is a clinically relevant side-effect of radiotherapy delivered for pelvic cancers owing to the irradiation of the bowel, and the number of patients who develop chronic gastrointestinal symptoms after pelvic radiotherapy is greater than those with Crohn ’s disease[1]. Pelvic nodal irradiation (PNI) is delivered with the intent of eradicating lymph-nodal micrometastases, in both radical and post-prostatectomy settings, in the treatment of pelvic malignancies such as prostate, rectal or gynecologic cancers. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - January 7, 2024 Category: Radiology Authors: Giuseppe Sanguineti, Maddalena Pavarini, Fernando Munoz, Alessandro Magli, Domenico Cante, Elisabetta Garibaldi, Andrea Gebbia, Barbara Noris Chiorda, Giuseppe Girelli, Elisa Villa, Adriana Faiella, Justyna Magdalena Waskiewicz, Barbara Avuzzi, Alice Past Tags: Original Article Source Type: research
Non-invasive decision support for clinical treatment of NSCLC using a multiscale radiomics approach
Immunotherapy and targeted therapies have significantly transformed the treatment of various cancers. Immune checkpoint blockade with immunotherapeutic agents has shown promising results in the clinical management of lung cancer by preventing tumor cells from evading immune system surveillance [1,2]. Programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are the most extensively studied therapeutic targets. Accumulating studies have shown that the response to PD-1/PD-L1 immunotherapy is associated with tumor-infiltrating immune cells, to which immunoinflammatory tumors tend to respond [3,4]. (Sou...
Source: Radiotherapy and Oncology - January 7, 2024 Category: Radiology Authors: Xingping Zhang, Guijuan Zhang, Xingting Qiu, Jiao Yin, Wenjun Tan, Xiaoxia Yin, Hong Yang, Hua Wang, Yanchun Zhang Source Type: research
Intratumor genetic heterogeneity and head and neck cancer relapse
Head and neck squamous cell carcinoma (HNSCC) develops in the epithelial cells of the mucosal lining of the upper aerodigestive tract. HNSCC is one of the more common cancers with approximately 900,000 new cases per year diagnosed worldwide [1,2]. Exogenous carcinogens such as tobacco and alcohol are the classic risk factors for HNSCC. More recently a persistent infection with the human papillomavirus (HPV) has been recognized as risk factor [3], particularly in oropharyngeal squamous cell carcinomas (OPSCC). (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - January 5, 2024 Category: Radiology Authors: A.S. Pierik, J.B. Poell, A. Brink, M. Stigter- van Walsum, R.H. de Roest, T. Poli, A. Yaromin, P. Lambin, C.R. Leemans, R.H. Brakenhoff Tags: Original Article Source Type: research
Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy: a propensity score-matched cohort study
Nasopharyngeal carcinoma (NPC) is different from other subtypes of head and (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - January 5, 2024 Category: Radiology Authors: Fang Wang, Lu Zhou, Li-Jun Zhang, Chang-Bin Xie, Zhi-Wei Liao, Xiao-Dan Lin, Yue-Feng Wen Tags: Original Article Source Type: research
Pulmonary vein dose and risk of atrial fibrillation in patients with non-small cell lung cancer following definitive radiotherapy: an NI-HEART analysis
Radiotherapy (RT) is the only definitive treatment option available to patients with non-small cell lung cancer (NSCLC) deemed to be technically or medically inoperable. Contemporary RT results have been improved by the recent introduction of adjuvant immunotherapy, but outcomes remain poor, with (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - January 4, 2024 Category: Radiology Authors: Gerard M Walls, Conor McCann, John O'Connor, Anna O'Sullivan, David I Johnston, Jonathan McAleese, Conor K McGarry, Aidan J Cole, Suneil Jain, Karl T Butterworth, Gerard G Hanna Tags: Original Article Source Type: research
Selectively sparing of the supraclavicular area during intensity-modulated radiotherapy in nasopharyngeal carcinoma: A double-center observation study
As a consequence of the current excellent loco-regional control rates attained using the generally accepted treatment paradigms involving IMRT for nasopharyngeal carcinoma (NPC), reducing the toxicity of treatment and improving the patient's quality of life (QoL) is particularly important[1-3]. The lower neck in selective omitting clinical target volume (CTV) is one of the areas being explored[4-7].Published literature have confirmed the feasibility of elective ipsilateral upper-neck irradiation with sparing the lower neck in N0 and the contralateral lower neck in N1 and N3 disease[7-12]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - January 4, 2024 Category: Radiology Authors: Qiaojuan Guo, Tianzhu Lu, Wanfang Huang, Hanchuan Xu, Quxia Zhang, Yun Xiao, Jing Zhong, Honghui Xie, Jihong Chen, Jingfeng Zong, Xiaochang Gong, Jianji Pan, Jingao Li, Shaojun Lin Tags: Original Article Source Type: research
Aims+Scope/Editorial Board/ Publication information
(Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - January 1, 2024 Category: Radiology Source Type: research
Contents
(Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - January 1, 2024 Category: Radiology Source Type: research
Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells – implications for systemic control
Patients with high-grade prostate cancer (PCa) are at significant risk for local and distant relapse post treatment. High dose rate brachytherapy (BT) may improve PCa-specific survival and distant metastasis-free survival (DMFS) compared to external beam radiotherapy (EBRT) in conjunction with androgen deprivation therapy (ADT) in Gleason (Gl) 9-10 patients[1,2]. This suggests that BT, despite being a local treatment, may potentially induce immune activation resulting in enhanced systemic control. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - January 1, 2024 Category: Radiology Authors: H. Wang, L. Mendez, G. Morton, A. Loblaw, H.T. Chung, P. Cheung, A. Mesci, V. Escueta, T.N. Petchiny, X. Huang, S.D. White, M. Downes, D. Vesprini, S.K. Liu Tags: Short Communication Source Type: research
LUMINA: Using molecular biomarkers to guide decision making for breast radiotherapy
In this opinion piece, we respond to comments about the LUMINA trial by Meattini and colleagues in the Journal. LUMINA was a prospective cohort study which evaluated the omission of radiotherapy after breast conserving surgery (BCS) in patients treated with endocrine therapy with low risk clinico-pathologic features and luminal A breast cancer. We address their areas of concern including the single cohort design that required careful patient selection, the relatively short follow-up period of 5 years, and the limited follow-up on younger patients. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - December 30, 2023 Category: Radiology Authors: Timothy J. Whelan, Anthony Fyles, Sameer Parpia, Torsten Nielsen, Mark N. Levine Source Type: research
